This table from the Duesbery lab shows primary references relating to the roles of MKK signaling and embryonic vascularization revealed in gene targeting experiments. This table was featured in Oncogene
:
Depeille PE, Ding Y, Bromberg-White JL, Duesbery NS (2007). MKK signaling and vascularization. Oncogene
. 26(9):1290-6.
| Tier in Kinase Cascade |
Protein |
Gene Symbol |
Chr. (Human) |
Ensembl Gene ID |
Time of Death; observed vascular phenotype of knock-out |
References |
MKKK MEKK |
B-Raf |
BRAF |
7q34 |
ENSG00000157764  |
E 10.5 - E12.5 ; lack of circulation in yolk sac, enlarged and irregular blood vessels incompletely lined with endothelial cells |
(Wojnowski et al., 1997) |
| Raf-1 |
ARAF |
Xp11.23 |
ENSG00000078061  |
E10; reduced blood vessels in yolk sac (C57/BL6) and placenta (MF-1) |
(Huser et al., 2001) |
| MEKK1 |
MAP3K1 |
5q11.2 |
ENSG00000095015  |
E14.5; defect in definitive erythropoiesis |
(Bonnesen et al., 2005) |
| MEKK3 |
MAP3K3 |
17q23.3 |
ENSG00000198909  |
E11; reduced blood vessels in extraembryonic and embryonic tissues |
(Yang et al., 2000) |
| MEKK4 |
MAP3K4 |
6q26 |
ENSG00000085511  |
none noted (neural tube defects) |
(Chi et al., 2005) |
|
MKK MEK MAPKK |
MEK1 |
MAP2K1 |
15q22.31 |
ENSG00000169032  |
E10.5; reduced blood vessels in labyrinthine layer of placenta |
(Giroux et al., 1999) |
| MEK2 |
MAP2K2 |
19p13.3 |
ENSG00000126934  |
none noted (no adverse effects upon health) |
(Belanger et al., 2003) |
| MKK3 |
MAP2K3 |
17p11.2 |
ENSG00000034152  |
none noted (defects in cytokine signaling and T-cells) |
(Lu et al., 1999 ; Tanaka et al., 2002) |
| MKK4 |
MAP2K4 |
17Pp12 |
ENSG00000065559  |
E10.5-E12.5; none noted (defects in hepatogenesis) |
(Ganiatsas et al., 1998; Nishina et al., 1999) |
| MEK5 |
MAP2K5 |
15q23 |
ENSG00000137764  |
E10.5; cardiovascular defects |
(Wang et al., 2005) |
| MKK6 |
MAP2K6 |
17q24.3 |
ENSG00000108984  |
none noted (T-cell defects) |
(Tanaka et al., 2002) |
| MAPK |
ERK1 |
MAPK3 |
16p11.2 |
ENSG00000102882  |
none noted (T-cell defects) |
(Pages et al., 1999) |
| ERK2 |
MAPK1 |
22q11.21 |
ENSG00000100030  |
E7.5-E11; reduced blood vessels in labyrinthine layer of placenta |
(Hatano et al., 2003; Saba-El-Leil et al., 2003) |
| P38 α |
MAPK14 |
6p21.31 |
ENSG00000112062  |
E10.5; reduced blood vessels in labyrinthine layer of placenta |
(Tamura et al., 2000) |
| P38 β |
MAPK11 |
22q13.33 |
ENSG00000185386  |
none noted (no adverse effects upon health) |
(Beardmore et al., 2005) |
| ERK5 |
MAPK7 |
17p11.2 |
ENSG00000166484  |
E10-E11; embryonic blood vessels fail to mature; disrupts vascular integrity in adult mice |
(Hayashi et al., 2004; Regan et al., 2002 ; Sohn et al., 2002; Yan et al., 2003) |
| JNK1 |
MAPK8 |
10q11.22 |
ENSG00000107643  |
none noted (T-cell defects) |
(Dong et al., 1998) |
| JNK2 |
MAPK9 |
5q35.3 |
ENSG00000050748  |
none noted (T-cell defects) |
(Yang et al., 1998) |
Abbreviations: ERK, extracellular signal-regulated kinase; JNK, jun kinase; MAPK, mitogen-activated protein kinase; MKK, mitogen-activated protein kinase kinase; MEKK, mitogen-activated protein kinase kinase kinase; MAPKK, mitogen-activated protein kinase kinase.